Pfizer：Sigvotatug vedotin failed in Phase III.

On June 22 local time, Pfizer announced the top-line results from the Phase III SigVie-002 study (formerly known as Be6A Lung-01) of Sigvotatug vedotin.

Sigvotatug vedotin is a potentially first-in-class ADC targeting integrin beta-6 (IB6), which Pfizer obtained through its acquisition of Seagen.

SigVie-002 is a randomized, Phase III, open-label study designed to evaluate the efficacy and safety of Sigvotatug vedotin compared with docetaxel in adults with previously treated non-small cell lung cancer. A total of 703 subjects were enrolled in the study, with the primary endpoint being overall survival (OS).

A Phase 3 study (Be6A Lung-02) is evaluating sigvotatug vedotin plus pembrolizumab as a first-line treatment for advanced NSCLC with high PD-L1 expression (≥50%) . Be6A Lung-02 is an ongoing trial with an estimated enrollment of 714 participants, with completion anticipated around 2028 

Buy Sigvotatug vedotin from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.